• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

With Unity Software, I Don't See the U-Turn Sign

A fundamental analyst is looking late to the party.
By BRUCE KAMICH
Jun 16, 2022 | 10:30 AM EDT

The share price of Unity Software ( U) has declined from $210 in November to just $30 in May -- a heart-stopping plunge that may have prompted one sell-side fundamental analyst to rate Unity a new "sell."
 
We rely on the the price action and our indicators for our guidance and have been cautious since our November 10 review and liquidated remaining longs with a $141 sell stop.
 
Let's check on U again. 
 
In the daily bar chart of U, below, we can see that the stock made a low in May on extremely heavy trading volume. Many times this kind of volume can mark an important low but U has failed to make much of a price recovery. The price of U is close to its 52-week low and weakness in the broader market is steering things lower and sending buyers into hiding.
 
The slope of the 50-day moving average line is negative as is the slope of the 200-day line. Prices are extended (oversold) below the 200-day line but that has not prompted much in the way of a price recovery.
 
The On-Balance-Volume (OBV) line has been weakening since November. The Moving Average Convergence Divergence (MACD) oscillator has been bearish since December. 
 
 
 
In the weekly Japanese candlestick chart of U, below, we see a bearish picture. No bottom reversal pattern to point out. The 40-week line is bearish as is the OBV line and the MACD oscillator.  
 
 
 
In this daily Point and Figure chart of U, below, we can see a downside price target of $20. 
 
 
In this weekly Point and Figure chart of U, below, we can see a target of $20 also. 
 
 
 
Bottom-line strategy: There are three types of analysis -- fundamental, technical and quantitative. None of these approaches are perfect so do not think I live in a glass house. I have recommended buying stocks that gapped sharply lower the next day. Not fun. Meanwhile, let's avoid the long side of U.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Software & Services | Technology | Analyst Actions

More from Stocks

Hopeful Investors Get Scraped by the Bear

James "Rev Shark" DePorre
Jun 28, 2022 4:24 PM EDT

Bulls hoped that a bottom had been found, but they overlooked the reasons behind the rally last week.

Bed Bath & Beyond's Weakness is Likely to Persist

Bruce Kamich
Jun 28, 2022 2:36 PM EDT

The shares have been in the single digits since early May.

Let's Look Under the 'Shell' of This ESG-Style Fund

Mark Abssy
Jun 28, 2022 2:00 PM EDT

One of the Nuveen Global Net-Zero Transition exchange-traded fund's largest holdings is Shell, so let's drill down on this supposedly environmentally friendly ETF.

Taking Another Look at ON Semiconductor's Charts

Bruce Kamich
Jun 28, 2022 1:43 PM EDT

Here's what to watch for.

Feeling Queasy Over Moderna's Outlook? Investors May Still Get Their Shot

Brad Ginesin
Jun 28, 2022 12:45 PM EDT

With an expected dip for 2023, the pharmaceutical company could see its mRNA technology win big over the long term -- and investors could be rewarded.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login